• ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers
  • OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo
  • PharmaMar Partners with Foundation for Women’s Cancer to Support D.C. National 5K Race
  • Study Examines Chemotherapy Options for Partially Platinum-Sensitive OC Patients
  • Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models
  • FDA OKs Mersana’s XMT-1536 for Clinical Investigation in Ovarian, Other Solid Tumors
  • Propanc Biopharma Seeks Orphan Drug Status for PRP, Its Lead Product for Ovarian Cancer Treatment
  • Small RNA Molecules Are Ancient Kill Switches that Cause Cancer Cell Death, Study Reveals
  • FDA to Review Genentech’s Avastin as Front-line Treatment for Advanced Ovarian Cancer
  • ICER Report Concludes Comparative Value of PARP Inhibitors is Lacking
  • Oncbiomune to Advance Ovarian Cancer Vaccine into Clinical Trials
  • Ovarian Cancer Gene Therapy Specialist Is One of Three Researchers Sharing $1.3 Million in Grants